Bioversys AG Working Capital to Net Assets Ratio
Bioversys AG working capital to net assets ratio. Bioversys AG (BIOV) has a Working Capital to Net Assets ratio of 147.9% as of June 2026. Working capital of CHF66.30 Million (current assets of CHF75.97 Million minus current liabilities of CHF9.67 Million) is measured against net assets of CHF44.84 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check how tangible is Bioversys AG's equity to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Bioversys AG (2024–2025)
Working capital to net assets ratio of Bioversys AG from 2024 to 2025. This chart shows how Bioversys AG's Working Capital to Net Assets ratio has evolved across 2 annual periods from 2024 to 2025. As of June 2026, the ratio stands at 147.9%, reflecting working capital of CHF66.30 Million against net assets of CHF44.84 Million CHF. See BIOV defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Bioversys AG Working Capital to Net Assets Ratio by Year (2024–2025)
Bioversys AG working capital to net assets ratio by year from 2024 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Bioversys AG from 2024 to 2025, covering 2 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see BIOV asset base.
| Year | WC/NA Ratio | Working Capital (CHF) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 135.4% | CHF80.97 Million | CHF59.81 Million | CHF89.87 Million | CHF8.90 Million | ▼ -96.1 pp |
| 2024 | 231.5% | CHF24.73 Million | CHF10.68 Million | CHF34.40 Million | CHF9.67 Million | — |